<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971669</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00040022</org_study_id>
    <nct_id>NCT03971669</nct_id>
  </id_info>
  <brief_title>Blood Donor CVD 5000</brief_title>
  <official_title>Collection of Blood Samples for In-Vitro Studies From Healthy Adult Blood Donors Who Have Received Oral Typhoid Vaccine (TY21A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid&#xD;
      oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA)&#xD;
      for travelers to developing countries. Volunteers will also be asked to provide blood,&#xD;
      saliva, and stool specimens over a follow-up time period of up to eight years. The specimens&#xD;
      obtained in this clinical research study will be used to further the investigator's&#xD;
      understanding of the protective immunological mechanisms that can be elicited systemically&#xD;
      and may be applicable to other enteric pathogens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2004</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Volunteers who choose to take part in this study will receive the licensed FDA-approved Oral Typhoid Vaccine (Vivotif).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>approximately 5 years</time_frame>
    <description>Percentage of responders by cytokine production (Interferon-gamma (IFN-gamma) or Tumor Necrosis Factor-alpha (TNF-α)) by mass cytometry or flow cytometry. Responders will be defined as those volunteers showing increases post-immunization of &gt;0.1% of positive CD8+ cells for IFN-gamma or TNF-α over baseline (pre-immunization) values.) or Tumor Necrosis Factor-alpha (TNF-α)) by mass cytometry or flow cytometry.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Risk Reduction</condition>
  <arm_group>
    <arm_group_label>Vaccination with Oral Typhoid Vaccine (Vivotif)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivotif Typhoid Oral Vaccine</intervention_name>
    <description>The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).</description>
    <arm_group_label>Vaccination with Oral Typhoid Vaccine (Vivotif)</arm_group_label>
    <other_name>Ty21a Typhoid Oral Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Good general health as determined by a screening evaluation within 28 days before&#xD;
             blood donation&#xD;
&#xD;
          -  Informed, written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any of the following medical illnesses:&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical&#xD;
                  carcinoma in situ)&#xD;
&#xD;
               -  Heart disease (Hospitalization for a heart attack, coronary artery bypass graft,&#xD;
                  arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease -&#xD;
                  dyspnea, angina, orthopnea)&#xD;
&#xD;
               -  Recurrent infections (more than 3 hospitalizations for invasive bacterial&#xD;
                  infections such as pneumonia or meningitis)&#xD;
&#xD;
               -  Current drug or alcohol abuse&#xD;
&#xD;
               -  Active ulcer disease or ongoing intestinal condition&#xD;
&#xD;
               -  Treatment for anemia in last 6 months&#xD;
&#xD;
               -  Currently being treated with anti-malarial drugs&#xD;
&#xD;
          -  Any of the following laboratory abnormalities detected during medical screening:&#xD;
&#xD;
               -  WBC &lt;0.81 x LLN or &gt; 1.09 x ULN&#xD;
&#xD;
               -  Hemoglobin &lt;0.91 x LLN or &gt;1.18 x ULN (women) or &lt;0.92 x LLN or &gt;1.18 x ULN (men)&#xD;
&#xD;
               -  Platelet count &lt;0.8 x LLN or &gt; 1.2 x ULN&#xD;
&#xD;
               -  (For leukopheresis or blood unit donations, the following lab values are&#xD;
                  exclusionary:&#xD;
&#xD;
               -  WBC &lt;3.5 or &gt;11 x 103/mm3;&#xD;
&#xD;
               -  Hemoglobin &lt;12.5 or &gt;18 g/dl&#xD;
&#xD;
               -  Platelet count &lt;150 or &gt;500 x 103/mm3)&#xD;
&#xD;
               -  SGOT or SGPT &gt;1.5 times normal&#xD;
&#xD;
               -  Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen&#xD;
&#xD;
               -  Positive serology for hepatitis B core antibody&#xD;
&#xD;
               -  Poor peripheral venous access for blood donation&#xD;
&#xD;
               -  Positive RPR&#xD;
&#xD;
          -  Other condition that in the opinion of the investigator would jeopardize the safety or&#xD;
             rights of a volunteer participating in the trial or interfere with the scientific&#xD;
             integrity of study.&#xD;
&#xD;
          -  Positive urine pregnancy test (HCG) on day of vaccination. Prior to each blood&#xD;
             donation -females with menstrual history consistent with pregnancy. Pregnant women&#xD;
             will not be enrolled, because immunological changes that occur during pregnancy may&#xD;
             interfere with laboratory assays.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robin Barnes, CRNP</last_name>
    <phone>410-706-6156</phone>
    <email>rbarnes@som.umaryland.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland, Baltimore, Center for Vaccine Development and Global Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Barnes, CRNP</last_name>
      <phone>410-706-6156</phone>
      <email>rbarnes@som.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Marcelo Sztein</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Typhoid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

